|
ZA200402530B
|
|
Use of histamine to treat liver disease.
|
|
AU2004201142A1
|
|
Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
|
|
AU2003271379A1
|
|
Activation and protection of T-cells (CD4+ and CD8+) using H2 receptor agonist and other T-cell activating agents
|
|
WO03082081A2
|
|
Use of rom production and release inhibitors to treat and prevent intraocular damage
|
|
CA2466083A1
|
|
Compositions for the treatment of infectious diseases
|
|
IL160928D0
|
|
Use of histamine to treat liver disease
|
|
AU9711701A
|
|
Administration of histamine for therapeutic purposes
|
|
EP1326629A2
|
|
Methods and compositions for promoting the maturation of monocytes
|
|
AU6751000A
|
|
Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
|
|
NZ515859A
|
|
Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
|
|
CA2376108A1
|
|
Ophthalmic histamine compositions and uses thereof
|
|
AU3343500A
|
|
Synergistic tumorcidal response induced by histamine
|
|
US6155266A
|
|
Method for treatment of cancer and infectious disease
|
|
AU2482500A
|
|
Synthesis of histamine dihydrochloride
|
|
IL141627D0
|
|
Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents
|
|
AU4462899A
|
|
Immunogens for stimulating mucosal immunity
|
|
AU2232399A
|
|
Recombinant ctb-based vaccines
|
|
US6270781B1
|
|
Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
|
|
US6242473B1
|
|
Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
|
|
US6003516A
|
|
Method for treatment of cancer and infectious disease
|
